AstraZeneca's Imfinzi fails main goal in advanced cervical cancer study
Send a link to a friend
 [March 24, 2022]
(Reuters) -AstraZeneca said on
Thursday its drug Imfinzi, along with chemoradiotherapy, failed to
achieve the main goal of improving survival in patients with locally
advanced cervical cancer without the disease worsening.
The late-stage study, dubbed "CALLA", tested progression-free survival
of patients with the combination against chemoradiotherapy alone, the
drugmaker said, and the results are seen as a setback for its efforts in
a major area of focus.
Imfinzi belongs to the immunotherapy class of treatments that boost the
body's own defences to fight cancer by using antibodies that block or
bind to foreign substances in the body.
The treatment, mainly a lung cancer therapy, generated $2.41 billion in
2021 sales, and is currently under development and regulatory review for
other cancer indications as well, including tumours in the bladder.
[to top of second column]
|
A company logo is seen at the AstraZeneca site in Macclesfield,
Britain, May 11, 2021. REUTERS/Phil Noble/File Photo
 "While the results were not what we
hoped for, insights from the trial will advance our understanding
and application of immunotherapy across our broad clinical
development programme," Susan Galbraith, executive vice president of
oncology R&D at AstraZeneca, said in a statement.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Sherry
Jacob-Phillips and Sriraj Kalluvila)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
